UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

Current Report Pursuant

to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): August 1525, 2025

THERAVANCE BIOPHARMA, INC.

(Exact Name of Registrant as Specified in its Charter)

Cayman Islands	001-36033	98-1226628
(State or Other Jurisdiction of	(Commission File Number)	(I.R.S. Employer Identification
Incorporation)		Number)

c/o Theravance Biopharma US, LLC

901 Gateway Boulevard

South San Francisco, CA 94080

(650) 808-6000

(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Ordinary Share $0.00001 Par Value		TBPH		NASDAQ Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company    ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01 Other Events

On August 1525, 2025, Theravance Biopharma ~~R&D IP~~, ~~LLC, Theravance Biopharma US, LLC and Theravance Biopharma Ireland Limited, subsidiaries of the Registrant Theravance Biopharma,~~ Inc. (~~together,~~NASDAQ: ~~“Theravance”~~TBPH), announced ~~and~~that ~~Mylan~~it ~~Ireland~~completed ~~Limited~~enrollment ~~and~~in ~~Viatris~~the ~~Specialty~~open-label ~~L.P.~~portion ~~(together,~~of ~~“Mylan”),~~its ~~entered~~pivotal ~~into a~~Phase ~~Settlement~~3 ~~Agreement~~CYPRESS ~~(the~~study ~~“Settlement~~in ~~Agreement”)~~patients with ~~Cipla~~symptomatic ~~Limited and Cipla USA, Inc. (“Cipla”) relating~~neurogenic toorthostatic ~~Theravance~~hypotension ~~and Mylan’s YUPELRI®~~ (~~revefenacin~~nOH) ~~inhalation~~due ~~solution.~~to Amultiple ~~Theravance~~system ~~entity~~atrophy owns and Mylan is the exclusive sub-licensee of United States Patent Nos. 8,541,451; 9,765,028; 10,550,081; 11,008,289; 11,484,531; 11,691,948; 8,017,783; 9,249,099; 10,100,013; 11,649,209; 11,858,898, 12,048,692 and 12,285,417 (~~the “Patents-in-Suit”~~MSA).

~~The~~A ~~Settlement~~copy ~~Agreement~~of ~~resolves ongoing patent litigation brought by Theravance and Mylan against Cipla pursuant to~~ the ~~Hatch-Waxman~~press ~~Act~~release ~~based~~is onfurnished ~~Cipla’s~~as ~~filing~~Exhibit 99.1 ~~of an abbreviated new drug application (“ANDA”) seeking approval~~ to ~~market a generic version of YUPELRI® (revefenacin) inhalation~~this ~~solution~~Current ~~prior to expiration of the Patents-in-Suit~~Report.

~~Under~~The ~~the~~information ~~Settlement~~in ~~Agreement,~~this ~~Theravance~~Current ~~and~~Report (including Exhibit 99.1) ~~Mylan~~is ~~granted~~being ~~Cipla~~furnished aand ~~royalty-free,~~shall ~~non-exclusive~~not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as ~~non-sublicensable~~amended, ~~non-transferable~~or ~~license~~otherwise subject to ~~manufacture~~the ~~and~~liabilities ~~market~~of ~~Cipla’s generic~~that ~~version~~Section. ofThe ~~YUPELRI®~~information in this Current Report (~~revefenacin~~including Exhibit 99.1) shall ~~inhalation~~not ~~solution~~be inincorporated ~~the~~by ~~United~~reference ~~States~~into onany registration statement or ~~after~~other document pursuant to the ~~Licensed~~Securities ~~Launch~~Act ~~Date~~ of ~~April 23~~1933, ~~2039~~as amended, except ~~subject~~as toshall ~~certain~~be ~~exceptions~~expressly asset isforth ~~customary~~by inspecific ~~these~~reference ~~type~~in ofsuch ~~agreements~~filing.

AsItem ~~required by law, the settlement is subject to review by the U~~9.S01. ~~Department~~Financial ofStatements ~~Justice~~ and ~~the Federal Trade Commission~~Exhibits.

~~The patent litigation previously disclosed by the Company remains pending against one other ANDA filer: Mankind Pharma Ltd~~(d) Exhibits.~~, along with certain affiliates.~~

SIGNATURE

	99.1	Press Release dated August 25, 2025

	104	Cover Page Interactive Data File (cover page XBRL tags embedded within the Inline XBRL document)

~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~SIGNATURE

	THERAVANCE BIOPHARMA, INC.
Date: August 20, 2025	By:	/s/ Brett Grimaud
		Brett Grimaud
		General Counsel

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	THERAVANCE BIOPHARMA, INC.

Date: August 25, 2025	By:	/s/ Aziz Sawaf
		Aziz Sawaf
		Senior Vice President and Chief Financial Officer

Filing Compare · Theravance Biopharma, Inc.